Volume | 18,719 |
|
|||||
News | - | ||||||
Day High | 2.06 | Low High |
|||||
Day Low | 2.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aditxt Inc | ADTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.02 | 2.00 | 2.06 | 2.01 | 2.01 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
280 | 18,719 | $ 2.02 | $ 37,879 | - | 1.945 - 68.08 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:49:22 | 2 | $ 2.07 | USD |
Aditxt Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.35M | 1.67M | - | 645k | -32.7M | -19.64 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aditxt News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.10 | 2.2499 | 1.945 | 2.09 | 36,307 | 0.01 | 0.48% |
1 Month | 2.48 | 2.69 | 1.945 | 2.29 | 40,884 | -0.37 | -14.92% |
3 Months | 3.66 | 5.09 | 1.945 | 3.32 | 312,679 | -1.55 | -42.35% |
6 Months | 3.65 | 9.50 | 1.945 | 5.40 | 826,925 | -1.54 | -42.19% |
1 Year | 22.40 | 68.08 | 1.945 | 8.96 | 547,402 | -20.29 | -90.58% |
3 Years | 90.00 | 1,139.60 | 1.945 | 48.77 | 2,259,563 | -87.89 | -97.66% |
5 Years | 211.20 | 1,139.60 | 1.945 | 72.64 | 2,176,661 | -209.09 | -99.00% |
Aditxt Description
Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. |